WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma

Microbiology and Immunology

Volumn 51, Issue 5, 2007, Pages 519-530

  Iiyama, Tatsuo ^a   Udaka, Keiko ^a   Takeda, Sachihiko ^a   Takeuchi, Tamotsu ^a   Adachi, Yoshihiro C ^a   Ohtsuki, Yuji ^a   Tsuboi, Akihiro ^b   Nakatsuka, Shin Ichi ^c   Elisseeva, Olga A ^b   Oji, Yusuke ^b   Kawakami, Manabu ^b   Nakajima, Hiroko ^b   Nishida, Sumiyuki ^b   Shirakata, Toshiaki ^b   Oka, Yoshihiro ^b   Shuin, Taro ^a   Sugiyama, Haruo ^b  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c National Hospital Organization   (Japan)

Author keywords

Cytotoxic T lymphocytes; HLA; Peptide; Vaccine; WT1

Indexed keywords

ALPHA INTERFERON; CD8 ANTIGEN; CYSTEINYLTYROSYLTHREONYLTRYPTOPHYLASPARAGINYLGLUTAMINYLMETHIONYL ASPARAGINYLLEUCINE 235 243; FREUND ADJUVANT; HLA A ANTIGEN; PEPTIDE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

AGED; ANOREXIA; APPLICATION SITE ERYTHEMA; APPLICATION SITE REACTION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CASE REPORT; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EFFECTOR CELL; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; PHENOTYPE; SKIN INDURATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 34249106425     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2007.tb03940.x     Document Type: Article

References (52)

1. Anichini, A., Scarito, A., Molla, A., Parmiani, G., and Mortarini, R. 2003. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common γ-chain cytokines. J. Immunol. 171: 2134-2141.
2. Betts, M., Brenchley, J., Price, D., Rosa, S., Douek, D., Roederer, M., and Koup, R. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281: 65-78.
3. Brossart, P., Wirths, S., Stuhler, G., Reichardt, V., Kanz, L., and Brugger, W. 2000. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108.
4. Call, K.M., Glaser, T., Ito, C.Y., Buckler, A.J., Pelletier, J., Haber, D.A., Rose, E.A., Kral, A., Yeger, H., Lewis, W.H., Jones, C., and Housman, D. 1990. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520.
5. + T cells and monocyte/dendritic cell precursors. Cancer Res. 66: 4943-4950.
6. Elisseeva, O.A., Oka, Y., Tsuboi, A., Ogata, K., Wu, F., Kim, E.H., Soma, T., Tamaki, H., Kawakami, M., Oji, Y., Hosen, N., Kubota, T., Nakagawa, M., Yamagami, T., Hiraoka, A., Tsukaguchi, M., Udaka, K., Ogawa, H., Kishimoto, T., Nomura, T., and Sugiyama, H. 2002. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99: 3272-3279.
7. Gao, L., Bellantuono, I., Elsasser, A., Marley, S.B., Gordon, M.Y., Goldman, J.M., and Stauss, H.J. 2000. Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198-2203.
8. Gessler, M., Poustka, A., Cavenee, W., Neve, R.L., Orkin, S.H., and Bruns, G.A. 1990. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343: 774-778.
9. Gillmore, R., Xue, S.-A., Holler, A., Kaeda, J., Hadjiminas, D., Healy, V., Dina, R., Parry, S., Bellantuono, I., Ghani, Y., BCoombes, R., Waxman, J., and Stauss, H. 2006. Detection of Wilms' tumor antigen-specific CTL in tumordraining lymph nodes of patients with early breast cancer. Clin. Cancer Res. 12: 34-42.
10. Hamann, D., Baars, P., Rep, M., Hooibrink, B., Kerkhof-Garde, S., Klein, M., and van Lier, R. 1997. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186: 1407-1418.
11. Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., et al. 1994. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-3079.
12. Inoue, K., Tamaki, H., Ogawa, H., Oka, Y., Soma, T., Tatekawa, T., Oji, Y., Tsuboi, A., Kim, E.H., Kawakami, M., Akiyama, T., Kishimoto, T., and Sugiyama, H. 1998. Wilms' tumor gene (WT1) competes with differentiationinducing signal in hematopoietic progenitor cells. Blood 91: 2969-2976.
13. Knutson, K., Schiffman, K., Cheever, M., and Disis, M. 2002. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptidespecific immunity. Clin. Cancer Res. 8: 1014-1018.
14. Mailander, V., Scheibenbogen, C., Thiel, E., Letsch, A., Blau, I., and Keilholz, U. 2004. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18: 165-166.
15. Menke, A., van der Eb, A., and Jochemsen, A. 1998. The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? Int. Rev. Cytol. 181: 151-212.
16. Menssen, H.D., Renkl, H.J., Rodeck, U., Kari, C., Schwartz, S., and Thiel, E. 1997. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int. J. Cancer 70: 518-523.
17. Miyoshi, Y., Ando, A., Egawa, C., Taguchi, T., Tamaki, Y., Tamaki, H., Sugiyama, H., and Noguchi, S. 2002. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin. Cancer Res. 8: 1167-1171.
18. Mocellin, S., Rossi, C., Nitti, D., Lise, M., and Marincola, F. 2003. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochim. Biophys. Acta 1653: 61-71.
19. Monsurro, V., Nagorsen, D., Wang, E., Provenzano, M., Dudley, M.E., Rosenberg, S.A., and Marincola, F.M. 2002. Functional heterogeneity of vaccine-induced CD8 (+) T cells. J. Immunol. 168: 5933-5942.
20. + T cells can protect APC from CTL-mediated elimination. J. Immunol. 176: 7379-7384.
21. Murata, Y., Kudoh, T., Sugiyama, H., Toyoshima, K., and Akiyama, T. 1997. The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. FEBS Lett. 409: 41-45.
22. Murray, J., Gillogly, M., Przepiorka, D., Brewer, H., Ibrahim, N., Booser, D., Hortobagyi, G., Kudelka, A., Grabstein, K., Cheever, M., and Ioannides, C. 2002. Toxicity, immunogenicity, and induction of E75-specific tumorlytic CTLs by HER-2 peptide E75(369-377) combined with granulocyte macrophage colony-stimulating factor in HLAA2+ patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 8: 3407-3418.
23. Nencioni, A., Guenebach, F., Patrone, F., and Brossart, P. 2004. Anticancer vaccination strategies. Ann. Oncol. 15: 153-160.
24. Ogawa, H., Tamaki, H., Ikegame, K., Soma, T., Kawakami, M., Tsuboi, A., Kim, E.H., Hosen, N., Murakami, M., Fujioka, T., Masuda, T., Taniguchi, Y., Nishida, S., Oji, Y., Oka, Y., and Sugiyama, H. 2003. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101: 1698-1704.
25. Ohminami, H., Yasukawa, M., and Fujita, S. 2000. HLA class I-restricted lysis of leukemia cells by a CD8 (+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95: 286-293.
26. Oji, Y., Miyoshi, S., Maeda, H., Hayashi, S., Tamaki, H., Nakatsuka, S., Yao, M., Takahashi, E., Nakano, Y., Hirabayashi, H., Shintani, Y., Oka, Y., Tsuboi, A., Hosen, N., Asada, M., Fujioka, T., Murakami, M., Kanato, K., Motomura, M., Kim, E.H., Kawakami, M., Ikegame, K., Ogawa, H., Aozasa, K., Kawase, I., and Sugiyama, H. 2002. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int. J. Cancer 100: 297-303.
27. Oji, Y., Miyoshi, Y., Koga, S., Nakano, Y., Ando, A., Nakatsuka, S., Ikeba, A., Takahashi, E., Sakaguchi, N., Yokota, A., Hosen, N., Ikegame, K., Kawakami, M., Tsuboi, A., Oka, Y., Ogawa, H., Aozasa, K., Noguchi, S., and Sugiyama, H. 2003. Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci. 94: 606-611.
28. Oji, Y., Ogawa, H., Tamaki, H., Oka, Y., Tsuboi, A., Kim, E. H., Soma, T., Tatekawa, T., Kawakami, M., Asada, M., Kishimoto, T., and Sugiyama, H. 1999. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer Res. 90: 194-204.
29. Oji, Y., Suzuki, T., Nakano, Y., Maruno, M., Nakatsuka, S., Jomgeow, T., Abeno, S., Tatsumi, N., Yokota, A., Aoyagi, S., Nakazawa, T., Ito, K., Kanato, K., Shirakata, T., Nishida, S., Hosen, N., Kawakami, M., Tsuboi, A., Oka, Y., Aozasa, K., Yoshimine, T., and Sugiyama, H. 2004. Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer. Sci. 95: 822-827.
30. Oka, Y., Elisseeva, O.A., Tsuboi, A., Ogawa, H., Tamaki, H., Li, H., Oji, Y., Kim, E.H., Soma, T., Asada, M., Ueda, K., Maruya, E., Saji, H., Kishimoto, T., Udaka, K., and Sugiyama, H. 2000. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product. Immunogenetics 51: 99-107.
31. Oka, Y., Tsuboi, A., Kawakami, M., Elisseeva, O., Nakajima, H., Udaka, K., Kawase, I., Oji, Y., and Sugiyama, H. 2006. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr. Med. Chem. 13: 2345-2352.
32. Oka, Y., Tsuboi, A., Murakami, M., Hirai, M., Tominaga, N., Nakajima, H., Elisseeva, O.A., Masuda, T., Nakano, A., Kawakami, M., Oji, Y., Ikegame, K., Hosen, N., Udaka, K., Yasukawa, M., Ogawa, H., Kawase, I., and Sugiyama, H. 2003. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78: 56-61.
33. Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O.A., Oji, Y., Kawakami, M., Ikegame, K., Hosen, N., Yoshihara, S., Wu, F., Fujiki, F., Murakami, M., Masuda, T., Nishida, S., Shirakata, T., Nakatsuka, S., Sasaki, A., Udaka, K., Dohy, H., Aozasa, K., Noguchi, S., Kawase, I., and Sugiyama, H. 2004. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. U.S.A. 101: 13885-13890.
34. Oka, Y., Udaka, K., Tsuboi, A., Elisseeva, O.A., Ogawa, H., Aozasa, K., Kishimoto, T., and Sugiyama, H. 2000. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J. Immunol. 164: 1873-1880.
35. Osaka, M., Koami, K., and Sugiyama, T. 1997. WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia. Int. J. Cancer 72: 696-699.
36. Peterson, A., Harlin, H., and Gajewski, T. 2006. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human Interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21: 2342-2348.
37. Rosenberg, S. 2001. Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.
38. + T cells in patients with melanoma. J. Immunol. 175: 6169-6176.
39. Rosenberg, S., Yang, J., Schwartzentruber, D., Hwu, P., Marincola, F., Topalian, S., Restifo, N., Dudley, M., Schwarz, S., Spiess, P., Wunderlich, J., Parkhurst, M., Kawakami, Y., Seipp, C., Einhorn, J., and White, D. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
40. Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., and Takahashi, T. 2001. Immunological tolerance maintained by CD25+CD4+ regulatory T cells; their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182: 18.
41. Scheibenbogen, C., Letsch, A., Thiel, E., Schmittel, A., Mailaender, V., Baerwolf, S., Nagorsen, D., and Keilholz, U. 2002. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100: 2132-2137.
42. Slingluff, C.L., Jr., Petroni, G.R., Yamshchikov, G.V., Barnd, D.L., Eastham, S., Galavotti, H., Patterson, J.W., Deacon, D.H., Hibbitts, S., Teates, D., Neese, P.Y., Grosh, W.W., Chianese-Bullock, K.A., Woodson, E.M., Wiernasz, C.J., Merrill, P., Gibson, J., Ross, M., and Engelhard, V.H. 2003. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21: 4016-4026.
43. Speiser, D., Lienard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A., Cerottini, J., and Romero, P. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptides, IFA, and CpG oligonucleotide 7909. J. Clin. Invest. 115: 739-746.
44. Tamaki, H., Ogawa, H., Ohyashiki, K., Ohyashiki, J.H., Iwama, H., Inoue, K., Soma, T., Oka, Y., Tatekawa, T., Oji, Y., Tsuboi, A., Kim, E.H., Kawakami, M., Fuchigami, K., Tomonaga, M., Toyama, K., Aozasa, K., Kishimoto, T., and Sugiyama, H. 1999. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13: 393-399.
45. Therasse, P., Arbuck, S., Eisenhauer, E., Wanders, J., Kaplan, R., Rubinstein, L., Verweij, J., van Glabbeke, M., van Oosterom, A., Christian, M., and Gwyther, S. 2000. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer. Inst. 92: 205-216.
46. Thurner, B., Haendle, I., Roeder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., vonden Driesch, B., Brocker, E.B., Steinman, R.M., Enk, A., Kaempgen, E., and Schuler, G. 1999. Vaccination with Mage-3A1 peptide-pulsed mature, monocytederived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190: 1669-1678.
47. Tsuboi, A., Oka, Y., Ogawa, H., Elisseeva, O.A., Li, H., Kawasaki, K., Aozasa, K., Kishimoto, T., Udaka, K., and Sugiyama, H. 2000. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J. Clin. Immunol. 20: 195-202.
48. Tsuboi, A., Oka, Y., Ogawa, H., Elisseeva, O.A., Tamaki, H., Oji, Y., Kim, E.H., Soma, T., Tatekawa, T., Kawakami, M., Kishimoto, T., and Sugiyama, H. 1999. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk. Res. 23: 499-505.
49. Tsuboi, A., Oka, Y., Osaki, T., Kumagai, T., Tachibana, I., Hayashi, S., Murakami, M., Nakajima, H., Elisseeva, O.A., Fei, W., Masuda, T., Yasukawa, M., Oji, Y., Kawakami, M., Hosen, N., Ikegame, K., Yoshihara, S., Udaka, K., Nakatsuka, S., Aozasa, K., Kawase, I., and Sugiyama, H. 2004. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol. Immunol. 48: 175-184.
50. Tsuboi, A., Oka, Y., Udaka, K., Murakami, M., Masuda, T., Nakano, A., Nakajima, H., Yasukawa, M., Hiraki, A., Oji, Y., Kawakami, M., Hosen, N., Fujioka, T., Wu, F., Taniguchi, Y., Nishida, S., Asada, M., Ogawa, H., Kawase, I., and Sugiyama, H. 2002. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol. Immunother. 51: 614-620.
51. Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S., and Weber, J. 1999. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5: 2756-2765.
52. Yamagami, T., Sugiyama, H., Inoue, K., Ogawa, H., Tatekawa, T., Hirata, M., Kudoh, T., Akiyama, T., Murakami, A., and Maekawa, T. 1996. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87: 2878-2884.